相关实验视频

Updated: Jun 4, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

家庭事务:剖析对多发性骨髓瘤风险的遗传贡献

Saoirse Bodnar¹, Tehilla Brander², Julie Gold²

¹Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.

Seminars in hematology

|December 25, 2024

概括

多发性骨髓瘤 (MM) 风险受遗传因素的影响. 了解这些遗传联系可以改善癌症家族史的个体的风险评估.

科学领域:

血液学血液学血液学
遗传学是一个遗传学.
在瘤学瘤学.

背景情况:

多发性骨髓瘤 (MM) 的原因尚未完全理解,但越来越多地认识到遗传成分.
家庭聚类和遗传变异表明遗传倾向于MM.

研究的目的:

审查和综合当前关于导致多发性骨髓瘤风险的遗传因素的研究.
整合流行病学和基因组数据,以确定对MM的遗传易感性.
倡导在高风险人群中进行生殖线查.

主要方法:

综合流行病学和基因组学研究的文献综述.
对多发性骨髓瘤的家族聚类模式的分析.
对常见变异进行全基因组关联研究 (GWAS) 的评估.
在敏感性基因中探索罕见的高透性变异.

主要成果:

证据支持在多发性骨髓瘤病因学中存在显著的遗传成分.
全基因组关联研究已经确定了与MM风险相关的常见遗传变异.
特定基因中的罕见,高透性变异也可能导致MM易感.

结论:

遗传因素在多发性骨髓瘤易感性中起着至关重要的作用.
对于高风险个体 (例如,强烈的家族癌症史,个人癌症史,早期发病的MM) 建议进行常规的生殖线查.
对遗传影响的进一步研究可以完善MM风险评估策略.

更多相关视频

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

相关概念视频

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...